DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Hypereosinophilic Syndrome - Pipeline Review, H1 2017" report to their offering.
Hypereosinophilic Syndrome - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Hypereosinophilic Syndrome (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Hypereosinophilic Syndrome (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hypereosinophilic Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III and Phase II stages are 1 and 4 respectively.
Hypereosinophilic Syndrome (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Key Topics Covered:
- Hypereosinophilic Syndrome - Overview
- Hypereosinophilic Syndrome - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
- Hypereosinophilic Syndrome - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Hypereosinophilic Syndrome - Companies Involved in Therapeutics Development
- Bristol-Myers Squibb Company
- GlaxoSmithKline Plc
- Knopp Biosciences LLC
- Kyowa Hakko Kirin Co Ltd
- Stemline Therapeutics Inc
For more information about this report visit http://www.researchandmarkets.com/research/cfl2nv/hypereosinophilic